Lee, Yu-Lin; Lin, Kuan-Yin; Cheng, Shu-Hsing; Lu, Po-Liang; Wang, Ning-Chi; Ho, Mao-Wang; Yang, Chia-Jui; Liou, Bo-Huang; Tang, Hung-Jen; Huang, Shie-Shian; Huang, Sung-Hsi; Chen, Tun-Chieh; Lin, Chi-Ying; Lin, Shih-Ping; Lee, Yuan-Ti; Hung, Chien-Ching published the artcile< Dual therapy with dolutegravir plus boosted protease inhibitor as maintenance or salvage therapy in highly experienced people living with HIV>, Category: esters-buliding-blocks, the main research area is dolutegravir protease inhibitor antiHIV agent HIV; Antiretroviral resistance; Dyslipidaemia; Integrase strand transfer inhibitor; Two-drug regimen; Weight gain.
Real-world experience with dolutegravir (DTG) plus boosted protease inhibitor (bPI) as a two-drug regimen is limited for highly experienced HIV-pos. patients with virol. failure or intolerance to antiretroviral therapy. Patients receiving DTG plus bPI between Sept. 2016 and June 2019 at 15 designated hospitals for HIV care in Taiwan were retrospectively included in this study. A standardised case record form was used to collect clin. data. The primary endpoint was virol. response, defined as achieving or maintaining plasma HIV-RNA <50 copies/mL at Week 48. A total of 77 patients were included; 58 (75.3%) had documented genotypic resistance to 1-4 antiretroviral classes. The most commonly used PI was darunavir (87.0%; 67/77). Seven patients (9.1%) had no virol. data at Week 48, including three with loss to follow-up, one severe hyperlipidemia, one renal failure and cardiovascular disease, one superimposed HBV infection and one death from anal cancer. The virol. response rate increased from 59.7% at baseline to 90.9% at Week 24 and 85.7% at Week 48. The only patient (1.3%) with virol. failure at Week 48 had poor adherence and baseline low-level resistance to darunavir with resistance-associated mutations at M46L, I50V and V82A. Compared with baseline, mean total cholesterol increased by 20.1 mg/dL and weight by 2.8 kg at Week 48, while the estimated glomerular filtration rate decreased by 14.4 mL/min/1.73m2 (both P < 0.05). We conclude that a two-drug regimen containing DTG plus bPI was effective in highly-experienced HIV-pos. patients, but metabolic impact and weight gain should be closely monitored. International Journal of Antimicrobial Agents published new progress about Anti-HIV agents. 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, Category: esters-buliding-blocks.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics